Recent Updates
Recently added Catalysts
INVA Positive Sentiment

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Innoviva Specialty Therapeutics has announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been designated as finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award. This recognition highlights the company's commitment to developing effective treatments for infectious diseases and marks the third consecutive year of nominations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Three therapies nominated for a prestigious award.
  • Recognition for innovative infectious disease treatments.
  • Demonstrates ongoing success in pharmaceutical development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
3%
average across 3 past catalysts
Lead asset
GCS-100
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics prod

Frequently Asked Questions

What therapies did Innoviva announce as finalists?

Innoviva announced XACDURO, ZEVTERA, and NUZOLVENCE as finalists.

What award are Innoviva's therapies nominated for?

They are nominated for the 2026 Prix Galien USA Best Pharmaceutical Product Award.

How many years has Innoviva received nominations?

This is the third consecutive year Innoviva has received nominations.

What is the focus of Innoviva's nominated therapies?

The therapies focus on treating infectious diseases.

ShareAdd on Google
Tags: INVA Viatris Investor Conferences Healthcare Innoviva XACDURO ZEVTERA NUZOLVENCE Prix Galien
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$1119M liquidity · $0M/mo burn
Low dilution risk
Lead asset
GCS-100Phase 2
Chronic Lymphocytic Leukemia →

Catalyst track record

+24%
best trade around INVA's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for INVA.

See every catalyst's timing & PoA →